-
AbbVie Q3 2024 Financial statements
Financial statements
In Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
冀州市|
高淳县|
卓资县|
建宁县|
嘉义县|
松滋市|
沙湾县|
黎川县|
白玉县|
原平市|
山东省|
永昌县|
鄂托克前旗|
安国市|
东安县|
伊宁县|
淮北市|
新田县|
贞丰县|
黔东|
西丰县|
聊城市|
夹江县|
永登县|
涞源县|
巴彦淖尔市|
湖南省|
湘阴县|
荣昌县|
洛浦县|
北辰区|
平泉县|
三都|
图木舒克市|
石家庄市|
富阳市|
阿尔山市|
松阳县|
乌海市|
图片|
石泉县|